CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Neural-net Artificial Pancreas +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05876273
NCT05876273N/ACompleted
CompareCT.gov

Adaptive Motif-Based Control (AMBC): Pilot 1 - Neural Net Implementation of Automated Insulin Delivery

University of Virginia·interventional·Posted May 25, 2023·Updated Jul 31, 2024

In Brief

A clinical study evaluating Neural-net Artificial Pancreas and University of Virginia Model Predictive Control for Type1 Diabetes. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study is intended to assess a Neural-net Artificial Pancreas (NAP) implementation of an established AP controller - the University of Virginia Model Predictive Control Algorithm (UMPC). The health outcomes achieved on NAP will be compared to the health outcomes achieved on UMPC in a randomized crossover design. The investigators will consent up to 20 participants, ages ≥18.0, with a goal of completing 15 participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
202420252026
First PostedMay 25, 2023
Enrollment StartMay 30, 2023
Primary CompletionSep 8, 2023
Study CompletionSep 10, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.1 years ago

Interventions

Neural-net Artificial Pancreasdevice

NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

University of Virginia Model Predictive Controldevice

A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.